New Horizon Health Limited 

$0
0
+$0+0% Monday 00:00

统计

当日最高
-
当日最低
-
52周高点
-
52周低点
-
成交量
-
平均成交量
-
市值
0
市盈率
-
股息率
-
股息
-

财务

-10.52%利润率
未盈利
2018
2019
2020
2021
2022
111.88M营收
-11.77M净利润

其他人也在关注

此列表基于在 Stock Events 上关注 NHZHY 的用户自选生成。这不是投资建议。

竞争对手

此列表为基于近期市场事件的分析。并非投资建议。

关于

New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China.
Show more...
首席执行官
Mr. Yeqing Zhu
员工
1041
国家
德国
ISIN
US64551U1025

上市

0 Comments

分享你的想法

FAQ

New Horizon Health Limited 的股票代码是什么?
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,New Horizon Health Limited 的股票以代码 NHZHY 进行交易。
New Horizon Health Limited 去年的营收是多少?
New Horizon Health Limited 去年的营收为 111.88MUSD。
New Horizon Health Limited 去年的净利润是多少?
NHZHY 去年的净收益为 -11.77MUSD。
New Horizon Health Limited 有多少名员工?
截至四月 13, 2026,公司共有1,041名员工。
New Horizon Health Limited 属于哪个行业?
New Horizon Health Limited从事于其他行业。
New Horizon Health Limited 何时完成拆股?
New Horizon Health Limited 最近没有进行任何拆股。
New Horizon Health Limited 的总部在哪里?
New Horizon Health Limited 的总部位于 德国 的 Hangzhou。